Drug intelligence / Profile preview

ADG30

Development stage: Preclinical
Lead developer: Invivyd
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ADG30 is a **preclinical monoclonal antibody** developed by **Adagio Therapeutics** for the prevention and treatment of **COVID-19**. It is a **SARS-CoV-2 neutralizing antibody** designed to bind the viral **spike protein**, targeting a conserved region of the antigen in order to retain activity against multiple variants of concern. In company materials and related descriptions, ADG30 was positioned as a potential **cocktail partner for ADG20** and as part of a broader coronavirus antibody portfolio intended to address current and future SARS-CoV-2 variants.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on ADG30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADG30.

Explore the full profile